Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: A Korean Diabetes Association and Korean Society of Nephrology consensus statement

Diabetes is a leading cause of end-stage renal disease. Therefore, prevention of renal dysfunction is an important treatment goal in the management of diabetes. The data of landmark cardiovascular outcome trials of sodiumglucose cotransporter-2 (SGLT2) inhibitors showed profound reno-protective effe...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Tae Jung Oh, Ju-Young Moon, Kyu Yeon Hur, Seung Hyun Ko, Hyun Jung Kim, Taehee Kim, Dong Won Lee, Min Kyong Moon, The Committee of Clinical Practice Guideline, Korean Diabetes Association and Committee of the Cooperative Studies, Korean Society of Nephrology
פורמט: Artigo
שפה:Inglês
יצא לאור: The Korean Society of Nephrology 2020-09-01
סדרה:Kidney Research and Clinical Practice
נושאים:
diabetes mellitus
type 2
glomerular filtration rate
renal function
sodium-glucose transporter-2 inhibitors
גישה מקוונת:https://doi.org/10.23876/j.krcp.20.132
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים